Compare SPOT & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOT | MRNA |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.1B | 91.2B |
| IPO Year | 2015 | 2018 |
| Metric | SPOT | MRNA |
|---|---|---|
| Price | $581.29 | $196.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 41 | 23 |
| Target Price | ★ $635.60 | $164.53 |
| AVG Volume (30 Days) | 1.7M | ★ 11.3M |
| Earning Date | 10-22-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $13.51 | $24.09 |
| Revenue Next Year | $14.92 | $11.33 |
| P/E Ratio | $38.70 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $405.00 | $23.55 |
| 52 Week High | $635.00 | $280.80 |
| Indicator | SPOT | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 50.18 | 41.43 |
| Support Level | $457.84 | $181.02 |
| Resistance Level | $635.00 | $254.48 |
| Average True Range (ATR) | 19.42 | 18.33 |
| MACD | -4.81 | -7.45 |
| Stochastic Oscillator | 8.18 | 5.92 |
Spotify is the leading global music streaming service, with over 750 million monthly active users and nearly 300 million paying subscribers, with the latter constituting the firm's premium segment. Most of the firm's revenue and nearly all its gross profit come from subscribers, who pay a monthly fee to access a music library that includes most of the most popular songs ever recorded, including all from the major record labels. The firm also offers access to audiobooks and integrates podcasts within its standard music app. Podcast content is not exclusive and is typically free to access on other platforms. Ad-supported users can access a similar music catalog, but cannot customize a similar on-demand experience.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.